Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 30, 2005

Study Completion Date

August 31, 2007

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

rosiglitazone

DRUG

metformin

DRUG

PN2034

Trial Locations (20)

17011

Camp Hill Clinical Research Center, Camp Hill

27103

Piedmont Medical Research Associates, Winston-Salem

27609

Neem Research Group of Raleigh, Raleigh

28211

Medical Research Associates of Charlotte, Charlotte

28262

Neem Research Group of Charlotte, Charlotte

28601

Unifour Medical Research Associates, Hickory

29201

Neem Research Group, Columbia

29464

Palmetto Medical Research Associates, Mt. Pleasant

32720

University Clinical Research-DeLand, DeLand

32779

Genesis Research International, Longwood

33021

Center for Diabetes and Endocrine Care, Hollywood

33028

Andres Patron, DO PA, Pembroke Pines

33156

Baptist Diabetes Associates, Miami

33321

CLIRECO, Inc., Tamarac

67203

PRN of Kansas, Wichita

73103

COR Clinical Research, LLC, Oklahoma City

77386

Oaks Medical Center, Spring

97504

Clinical Research Institute of Southern Oregon, PC, Medford

06708

Phoenix Internal Medicine Associates, Waterbury

32789,

Endocrine Clinical Research, Winter Park

All Listed Sponsors
lead

Wellstat Therapeutics

INDUSTRY

NCT00110851 - Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet) | Biotech Hunter | Biotech Hunter